The Place of Blood Stem Cells in Allogeneic Transplantation

Russell, Nigel H.; Gratwohl, Aloïs; Schmitz, Norbert

doi:10.1046/j.1365-2141.1996.d01-1712.x

Cited by 79 publications

(69 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second transplants following the procurement of additional marrow from the original donor have been performed, although their success rate has been variable (Bortin et al, 1993). As an increasing number of allogeneic PBSC transplantations are now being performed (Russell et al, 1996), the issue of second PBSC donations would be expected to emerge in the future. The current literature contains very limited data on the feasibility and apheresis yield of second PBSC donations.…”

Section: Discussionmentioning

confidence: 99%

“…It is unclear whether second PBSC collections (particularly if performed soon after the first) are associated with similar apheresis yields or whether G-CSF exposure impacts the subsequent PBSC mobilization efficiency. Available literature on allogeneic PBSC transplantation (Goldman, 1995;Russell et al, 1996;Lane, 1996) has not addressed this issue. At our institution we have had now the opportunity to perform a sizeable number of second PBSC collections.…”

mentioning

confidence: 99%

“…The avoidance of general anaesthesia or invasive procedures, as well as blood transfusions (Anderlini et al, 1996c;Russell et al, 1996;Dreger et al, 1994), makes this approach particularly attractive for repeated PBSC collections, which may be required to treat post-transplant relapse or graft failure. It is unclear whether second PBSC collections (particularly if performed soon after the first) are associated with similar apheresis yields or whether G-CSF exposure impacts the subsequent PBSC mobilization efficiency.…”

mentioning

confidence: 99%

“…Filgrastim-related adverse events were comparable. These data suggest that second PBSC collections are feasible, similarly tolerated and provide comparable apheresis yields.Keywords: peripheral blood stem cell(s), filgrastim, normal donors, allogeneic blood stem cell transplantation.G-CSF-mobilized peripheral blood stem cells (PBSCs) are increasingly viewed as a promising alternative to marrow for allografting in patients with haematological malignancies (Goldman, 1995;Russell et al, 1996;Lane, 1996). The avoidance of general anaesthesia or invasive procedures, as well as blood transfusions (Anderlini et al, 1996c;Russell et al, 1996;Dreger et al, 1994), makes this approach particularly attractive for repeated PBSC collections, which may be required to treat post-transplant relapse or graft failure.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections

et al. 1997

View full text Add to dashboard Cite

Summary. We report 13 normal peripheral blood stem cell (PBSC) donors who had a second PBSC collection for allogeneic transplantation performed after the first. The median interval between the first and second collection was 5 months. Mobilization was achieved with filgrastim (12 mg/ kg/d). No significant difference was found in the median pre-apheresis leucocyte count (×10 9 /l) between the two donations (40 . 2 v 38 . 5; P ¼ 0 : 91). The median apheresis yield (×10 6 CD34 þ cells/litre blood processed, first apheresis) was also similar (28 v 27 . 3; P ¼ 0 : 91). Filgrastim-related adverse events were comparable. These data suggest that second PBSC collections are feasible, similarly tolerated and provide comparable apheresis yields.Keywords: peripheral blood stem cell(s), filgrastim, normal donors, allogeneic blood stem cell transplantation.G-CSF-mobilized peripheral blood stem cells (PBSCs) are increasingly viewed as a promising alternative to marrow for allografting in patients with haematological malignancies (Goldman, 1995;Russell et al, 1996;Lane, 1996). The avoidance of general anaesthesia or invasive procedures, as well as blood transfusions (Anderlini et al, 1996c;Russell et al, 1996;Dreger et al, 1994), makes this approach particularly attractive for repeated PBSC collections, which may be required to treat post-transplant relapse or graft failure. It is unclear whether second PBSC collections (particularly if performed soon after the first) are associated with similar apheresis yields or whether G-CSF exposure impacts the subsequent PBSC mobilization efficiency. Available literature on allogeneic PBSC transplantation (Goldman, 1995;Russell et al, 1996;Lane, 1996) has not addressed this issue. At our institution we have had now the opportunity to perform a sizeable number of second PBSC collections. We therefore reviewed our donor database to report our experience. DONORS AND METHODS Normal apheresis donors.We retrospectively reviewed our PBSC donor database during a 18-month period ( January 1995/June 1996. During this time a total of 181 donors underwent PBSC collections after filgrastim mobilization for allografting in HLA-compatible related patients with haematological malignancies. 16 of them (9%) donated a second time at least 4 weeks after the first. In two of them the exact number of CD34 þ cells in the apheresis product could not be determined because of complex manipulations performed immediately after collection, and the apheresis charts of one donor were not available for review. These donors were considered inevaluable. The others (n ¼ 13) were included in the study. The protocol for PBSC collection was approved by the Institutional Review Board and written informed consent was obtained from each donor.Mobilization and apheresis. PBSC donors received daily filgrastim (6 mg/kg subcutaneously every 12 h) followed by daily continuous-flow leukapheresis through a bilateral peripheral venous access generally beginning on day 4 or day 5 of filgrastim administration. The amount of blood to be p...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Hematopoetic stem cell transplants have become established therapy for many congenital or acquired disorders of the hematopoietic system and for chemo-or radiosensitive malignancies. [2][3][4][5] Stem cell source has changed from bone marrow to peripheral blood [6][7][8] and includes in most recent times cord blood. 9,10 Donors for allogeneic transplants include HLA-identical siblings, HLA-mismatched relatives or unrelated volunteers.…”

mentioning

confidence: 99%